Latest Period
Q1 2026
Security Snapshot
NEPHROS INC - Common Stock - $0.001 par value (NEPH) Institutional Ownership
CUSIP: 640671400
13F Institutional Holders and Ownership History from Q3 2019 to Q1 2026
Institutions Reporting
27
Shares (Excl. Options)
5,370,279
Price
$2.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock - $0.001 par value
- Symbol
- NEPH on Nasdaq
- Shares outstanding
- 10,630,964
- Price per share
- $2.87
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,370,279
- Total reported value
- $16,003,262
- % of total 13F portfolios
- 0%
- Share change
- +66,716
- Value change
- -$116,419
- Number of holders
- 27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- NEPH - NEPHROS INC - Common Stock - $0.001 par value is tracked under CUSIP 640671400.
- 27 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 35 to 27 between Q4 2025 and Q1 2026.
- Reported value moved from $25,875,168 to $16,003,262.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 27 institutions filings for Q1 2026.
Security key
640671400
Latest holder period
Q1 2026
13F holders
27
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
NEPH full holder history
NEPHROS INC SEC filings
NEPHROS INC company facts
NEPHROS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640671400:
Significant Owners of NEPHROS INC - Common Stock - $0.001 par value (NEPH) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Topline Capital Management, LLC | 5.6% | $2,815,930 | 595,334 | Topline Capital Management, LLC | 04 Aug 2025 |
As of 31 Mar 2026, 27 institutional investors reported holding 5,370,279 shares of NEPHROS INC - Common Stock - $0.001 par value (NEPH). This represents 51% of the company’s total 10,630,964 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of NEPHROS INC - Common Stock - $0.001 par value (NEPH) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| WEXFORD CAPITAL LP | 34% | 3,600,552 | -0.46% | 1.8% | $10,729,646 |
| Topline Capital Management, LLC | 5.5% | 581,967 | -5.3% | 0.29% | $1,734,262 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 198,643 | 0% | 0% | $591,956 |
| Cornerstone Capital, Inc. | 1.2% | 128,700 | 0.04% | $383,526 | |
| BARD ASSOCIATES INC | 1.1% | 121,202 | -0.34% | 0.09% | $361,182 |
| Mesirow Financial Investment Management, Inc. | 1.1% | 120,000 | +140% | 0.01% | $357,600 |
| MORGAN STANLEY | 1% | 110,915 | +518% | 0% | $330,527 |
| RENAISSANCE TECHNOLOGIES LLC | 0.94% | 99,400 | -4.2% | 0% | $296,212 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.69% | 72,925 | -2.3% | 0% | $217,376 |
| HighTower Advisors, LLC | 0.56% | 59,710 | 0% | 0% | $177,936 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 0.37% | 38,984 | 0% | 0.02% | $116,172 |
| VANGUARD FIDUCIARY TRUST CO | 0.35% | 36,901 | 0% | 0% | $109,965 |
| BLAIR WILLIAM & CO/IL | 0.34% | 36,249 | 0% | 0% | $108,022 |
| De Lisle Partners LLP | 0.24% | 25,000 | 0% | 0.01% | $74,500 |
| CITADEL ADVISORS LLC | 0.2% | 20,888 | +0.86% | 0% | $62,246 |
| DIMENSIONAL FUND ADVISORS LP | 0.2% | 20,745 | +53% | 0% | $61,820 |
| NAVELLIER & ASSOCIATES INC | 0.18% | 19,126 | -30% | 0.01% | $56,995 |
| STATE STREET CORP | 0.15% | 15,698 | 0% | 0% | $46,780 |
| GOLDMAN SACHS GROUP INC | 0.13% | 14,163 | -25% | 0% | $42,206 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.13% | 13,680 | -9.9% | 0% | $40,766 |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 0.11% | 12,000 | +71% | 0.02% | $35,760 |
| Cannell & Spears LLC | 0.1% | 11,000 | 0% | 0% | $32,780 |
| NORTHERN TRUST CORP | 0.1% | 10,828 | 0% | 0% | $32,267 |
| ROYAL BANK OF CANADA | 0.01% | 747 | +1.2% | 0% | $2,000 |
| OSAIC HOLDINGS, INC. | 0% | 175 | -89% | 0% | $521 |
Institutional Holders of NEPHROS INC - Common Stock - $0.001 par value (NEPH) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,370,279 | $16,003,262 | -$116,419 | $2.98 | 27 |
| 2025 Q4 | 5,302,280 | $25,875,168 | +$1,403,304 | $4.88 | 35 |
| 2025 Q3 | 5,015,032 | $23,721,183 | +$770,357 | $4.73 | 23 |
| 2025 Q2 | 4,852,312 | $19,846,026 | +$767,466 | $4.09 | 20 |
| 2025 Q1 | 4,664,676 | $8,023,335 | -$71,094 | $1.72 | 17 |
| 2024 Q4 | 4,711,852 | $6,907,601 | +$947 | $1.47 | 17 |
| 2024 Q3 | 4,284,771 | $7,333,250 | -$66,476 | $1.71 | 17 |
| 2024 Q2 | 4,320,368 | $9,159,330 | +$116,985 | $2.11 | 18 |
| 2024 Q1 | 4,264,479 | $9,398,998 | -$169,208 | $2.19 | 18 |
| 2023 Q4 | 4,331,833 | $14,986,626 | +$148,381 | $3.46 | 18 |
| 2023 Q3 | 4,288,960 | $6,347,955 | +$12,732 | $1.48 | 14 |
| 2023 Q2 | 4,279,808 | $6,634,282 | +$34,065 | $1.55 | 15 |
| 2023 Q1 | 4,273,188 | $4,574,310 | +$8,159 | $1.07 | 17 |
| 2022 Q4 | 4,266,471 | $4,940,524 | -$78,172 | $1.16 | 18 |
| 2022 Q3 | 4,339,484 | $3,949,000 | +$17,380 | $0.91 | 17 |
| 2022 Q2 | 632,473 | $968,000 | -$108,653 | $1.53 | 15 |
| 2022 Q1 | 643,171 | $2,827,000 | -$4,636,503 | $4.39 | 13 |
| 2021 Q4 | 1,550,944 | $9,151,000 | -$931,227 | $5.90 | 11 |
| 2021 Q3 | 1,700,497 | $14,914,000 | +$362,427 | $8.77 | 13 |
| 2021 Q2 | 5,916,801 | $60,109,000 | +$672,777 | $10.15 | 15 |
| 2021 Q1 | 5,231,367 | $34,791,000 | -$660,885 | $6.65 | 17 |
| 2020 Q4 | 5,282,295 | $45,322,000 | +$2,352,286 | $8.58 | 14 |
| 2020 Q3 | 4,474,719 | $32,353,000 | -$269,921 | $7.23 | 15 |
| 2020 Q2 | 4,502,818 | $37,780,000 | +$1,367,226 | $8.39 | 17 |
| 2020 Q1 | 4,170,822 | $26,271,000 | +$23,387,609 | $6.30 | 18 |
| 2019 Q4 | 458,415 | $4,562,000 | +$176,424 | $9.95 | 12 |
| 2019 Q3 | 258,124 | $2,089,000 | +$2,089,000 | $8.07 | 7 |